GSK Extends Vaccine Collaboration in China with Zhifei

GlaxoSmithKline (GB:GSK) has released an update.

GSK has extended its collaboration with Chongqing Zhifei Biological Products to distribute its shingles vaccine, Shingrix, in China until 2034, while also exploring a new partnership on a respiratory syncytial virus vaccine. This strategic move could potentially generate £2.3 billion for GSK from Zhifei’s Shingrix purchases over the next six years. The collaboration aims to reach over 500 million people in China, enhancing vaccine availability in a rapidly growing market.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.